Syntactx
Business Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
150 Greenwich St Fl 44, New York City, N...Phone Number
(212) 228-9000Website
www.syntactx.comRevenue
$15 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Syntactx
NAMSA is a leading Medical Device Contract Research Organization (CRO) specializing in preclinical and clinical research, biological safety testing, and regulatory compliance for medical devices and IVDs. With over 1,400 professionals, they offer a comprehensive range of services including consulting, preclinical research, clinical trials, and medical device testing, focusing on ensuring the safety and compliance of medical devices globally. Their expertise spans a wide spectrum of therapeutic areas, and their services cater to manufacturers in North America, Europe, and Asia, facilitating efficient pathways to market. NAMSA has conducted extensive testing and supported thousands of medical device manufacturers worldwide, establishing themselves as a trusted partner in the industry.Explore more
Syntactx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Syntactx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Syntactx recently announced quarterly report
Funding: Get notified immidiatlly once Syntactx has new funding data
Congratulate Masked Content for being promoted to Masked Content at Syntactx
Website visits: Recent activity has been detected on your website
Click to see if Syntactx had a recent Job posting/layoffs
Product Launch: Get notified when Syntactx launches new products
Check if Syntactx has recently received funding, and reach out quickly before it becomes old news!
Check out if Syntactx is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Syntactx, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Syntactx
Compare insights from companies similar to Syntactx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Syntactx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Syntactx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Syntactx.
Syntactx financials insights
Gather financial insights about Syntactx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$1M
Syntactx Tech Stack
A closer look at the technologies used by Syntactx
Syntactx News & Media
Syntactx Appoints Dorothy Abel as Vice President, Regulatory Strategy
Feb. 6, 2020 15:00 UTC Former U.S. FDA Reviewer for Endovascular Devices Joins Global CRO NEW YORK--( BUSINESS WIRE )-- Syntactx, a global, full-service clinical research organization (CRO) specializing in complex interventional medical device and pharmaceutical trials, announced that Ms. Dorothy Abel has joined the company as Vice President, Regulatory Strategy. In this newly established role, Dorothy oversees the development andSyntactx Appoints Dorothy Abel as Vice President, Regulatory Strategy
Former U.S. FDA Reviewer for Endovascular Devices Joins Global CRO (PRWeb February 06, 2020) Read the full story at https://www.prweb.com/releases/syntactx_appoints_dorothy_abel_as_vice_president_regulatory_strategy/prweb16881542.htmSyntactx Appoints Dorothy Abel as Vice President, Regulatory Strategy
NEW YORK--(BUSINESS WIRE)-- #CRO--Syntactx, a global, full-service clinical research organization (CRO) specializing in complex interventional medical device and pharmaceutical trials, announced that Ms. Dorothy Abel has joined the company as Vice President, Regulatory Strategy. In this newly established role, Dorothy oversees the development and execution of regulatory plans designed to help clients formulate their product development strategy to achieve market approvals and worldwide adoption.Syntactx Appoints Dorothy Abel as Vice President, Regulatory Strategy
Syntactx, a global, full-service clinical research organization (CRO) specializing in complex interventional medical device and pharmaceutical trials, announced that Ms. Dorothy Abel has joined the company as Vice President, Regulatory Strategy. In this newly established role, Dorothy oversees the development
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Syntactx
Sign Up For FreeTo access detailed company insights
NAMSA is a leading Medical Device Contract Research Organization (CRO) specializing in preclinical and clinical research, biological safety testing, and regulatory compliance for medical devices and IVDs. With over 1,400 professionals, they offer a comprehensive range of services including consulting, preclinical research, clinical trials, and medi... Read More
